PLX · Insider Trading
Protalix BioTherapeutics, Inc. Common Stock
Every open-market purchase and sale reported by PLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Aharon Schwartz | Director | A | +25,500 deriv. | — |
| 2026-09-04 | Zvi Shmuel Ben | Director | A | +25,500 deriv. | — |
| 2026-09-04 | Pol F Boudes | Director | A | +25,500 deriv. | — |
| 2026-09-04 | Dror Bashan | PRESIDENT AND CEO | A | +480,000 deriv. | — |
| 2026-09-04 | Eliot Forster | Director | A | +25,500 deriv. | — |
| 2026-09-04 | Yaron Naos | Sr. VP & COO | A | +168,000 deriv. | — |
| 2026-09-04 | Christian Elze | Director | A | +25,500 deriv. | — |
| 2026-09-04 | Amos Bar-Shalev | Director | A | +25,500 deriv. | — |
| 2026-09-04 | Gwen A Melincoff | Director | A | +25,500 deriv. | — |
| 2025-12-23 | Dror Bashan | PRESIDENT AND CEO | Buy | +56,000 | +$101.36K |
| 2025-11-19 | Amos Bar-Shalev | Director | Sell | −168 | −$314 |
| 2025-09-04 | Gwen A Melincoff | Director | A | +7,500 | — |
| 2025-09-04 | Christian Elze | Director | A | +7,500 | — |
| 2025-09-04 | Zvi Shmuel Ben | Director | A | +7,500 | — |
| 2025-09-04 | Aharon Schwartz | Director | A | +7,500 | — |
| 2025-09-04 | Amos Bar-Shalev | Director | A | +7,500 | — |
| 2025-09-04 | Pol F Boudes | Director | A | +7,500 | — |
| 2025-09-04 | Dror Bashan | PRESIDENT AND CEO | A | +195,000 | — |
| 2025-09-04 | Yaron Naos | Sr. VP, Operations | A | +25,000 | — |
| 2025-09-04 | Eliot Forster | Director | A | +7,500 | — |
| 2025-08-12 | Aharon Schwartz | Director | Buy | +129,000 | +$205.88K |
| 2024-11-05 | Eyal Rubin | Sr. VP and CFO | A | +90,909 | — |
| 2024-09-24 | Yaron Naos | Sr. VP, Operations | A | +100,000 deriv. | — |
| 2024-09-24 | Eyal Rubin | Sr. VP and CFO | A | +99,010 | — |
| 2024-04-03 | Dror Bashan | PRESIDENT AND CEO | A | +263,960 | — |
| 2023-10-20 | Dror Bashan | PRESIDENT AND CEO | Buy | +64,516 | +$90.48K |
| 2023-10-03 | Zvi Shmuel Ben | Director | A | +61,676 deriv. | — |
| 2023-10-03 | Pol F Boudes | Director | A | +61,676 deriv. | — |
| 2023-10-03 | Aharon Schwartz | Director | A | +61,676 deriv. | — |
| 2023-10-03 | Amos Bar-Shalev | Director | A | +61,676 deriv. | — |
| 2023-10-03 | Gwen A Melincoff | Director | A | +61,676 deriv. | — |
| 2023-09-15 | Eliot Forster | Director | A | +85,715 deriv. | — |
| 2023-08-17 | Yaron Naos | Sr. VP, Operations | A | +187,344 | — |
| 2023-08-17 | Dror Bashan | President and CEO | A | +800,000 | — |
| 2023-08-17 | Eyal Rubin | Sr. VP and CFO | A | +201,903 | — |
| 2023-08-17 | Yael Hayon | VP, Research & Development | A | +35,115 | — |
| 2023-01-05 | Aharon Schwartz | Director | Buy | +110,000 | +$155.81K |
| 2022-09-09 | Pol F Boudes | Director | A | +50,000 deriv. | — |
| 2022-09-09 | Eyal Rubin | Sr. VP and CFO | A | +350,000 deriv. | — |
| 2022-09-09 | Dror Bashan | President and CEO | A | +750,000 deriv. | — |
| 2022-09-09 | Zvi Shmuel Ben | Director | A | +10,000 deriv. | — |
| 2022-09-09 | Yael Hayon | VP, Research & Development | A | +250,000 deriv. | — |
| 2022-09-09 | Amos Bar-Shalev | Director | A | +50,000 deriv. | — |
| 2022-09-09 | Gwen A Melincoff | Director | A | +50,000 deriv. | — |
| 2022-09-09 | Yaron Naos | Sr. VP, Operations | A | +340,000 deriv. | — |
| 2022-09-09 | Zeev Bronfeld | Director | A | +100,000 deriv. | — |
| 2022-09-09 | Aharon Schwartz | Director | A | +50,000 deriv. | — |
| 2022-07-05 | Zvi Shmuel Ben | Director | A | +40,000 deriv. | — |
| 2022-04-13 | Dror Bashan | President and CEO | Buy | +68,000 | +$102.00K |
| 2022-02-28 | Eyal Rubin | Sr. VP and CFO | A | +121,951 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Dror Bashan | PRESIDENT AND CEO | 2,532,934 | $7.04M |
| Eyal Rubin | Sr. VP and CFO | 660,909 | $1.84M |
| Aharon Schwartz | Director | 310,500 | $863.19K |
| Yaron Naos | Sr. VP & COO | 232,929 | $647.54K |
| Pol F Boudes | Director | 7,540 | $20.96K |
| Amos Bar-Shalev | Director | 7,500 | $20.85K |
| Gwen A Melincoff | Director | 7,500 | $20.85K |
| Eliot Forster | Director | 7,500 | $20.85K |
| Zvi Shmuel Ben | Director | 7,500 | $20.85K |
| Christian Elze | Director | 7,500 | $20.85K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PLX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.